title: Considerations on safety concerns about citalopram prescribing.
authors.affiliation: Department of Family Medicine, Mayo Clinic, Rochester, MN 55905, USA. sheeler.robert@mayo.edu
authors.forename: Robert D
authors.initials: RD
authors.lastname: Sheeler
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Ackerman
authors.forename: Elliott
authors.initials: E
authors.lastname: Richelson
authors.forename: Thomas K
authors.initials: TK
authors.lastname: Nelson
authors.forename: Jeffrey P
authors.initials: JP
authors.lastname: Staab
authors.forename: Eric G
authors.initials: EG
authors.lastname: Tangalos
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Dieser
authors.forename: Julie L
authors.initials: JL
authors.lastname: Cunningham
mesh_terms: D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use; D015283:Citalopram / Q000009:adverse effects* / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017277:Drug Approval; D016903:Drug Monitoring; D006329:Heart Conduction System / Q000187:drug effects; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000592:standards*; D017751:Safety Management / Q000592:standards*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D018687:Antidepressive Agents, Second-Generation; D015283:Citalopram; D017367:Selective Serotonin Reuptake Inhibitors